Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM . ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoRmSin3HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860–10865.
Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D . Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001; 11: 162–166.
Redner RL, Wang J, Liu JM . Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94: 417–428.
Bhalla KN . Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23: 3971–3993.
Kosugi H, Ito M, Yamamoto Y, Towatari M, Ito M, Ueda R et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice. Jpn J Cancer Res 2001; 92: 529–536.
Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77–84.
Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103: 4636–4643.
O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24: 166–173.
Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV, Suarez Nieto C et al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004; 164: 73–79.
Debret R, El Btaouri H, Duca L, Rahman I, Radke S, Haye B et al. Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells. FEBS Lett 2003; 546: 195–202.
Solito E, de Coupade C, Canaider S, Goulding NJ, Perretti M . Transfection of annexin 1 in monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with caspase-3 activation. Br J Pharmacol 2001; 133: 217–228.
Raynal P, Pollard HB . Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1994; 1197: 63–93.
Solito E, Kamal A, Russo-Marie F, Buckingham JC, Marullo S, Perretti M . A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J 2003; 17: 1544–1546.
Borisenko GG, Matsura T, Liu SX, Tyurin VA, Jianfei J, Serinkan FB et al. Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells – existence of a threshold. Arch Biochem Biophys 2003; 413: 41–52.
Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K et al. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 2005; 203: 387–397.
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM . Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest 1998; 101: 890–898.
Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-Cor and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176–7184.
Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW . The t(8;21) fusion product, AML1-ETO, associates with C/EBPα, inhibits C/EBPa-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 1998; 18: 322–333.
Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444–451.
Arur S, Uche UE, Rezaul K, Fong M, Scranton V, Cowan AE et al. Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev Cell 2003; 4: 587–598.
Gelmett V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA . Aberrant recruitment of the nuclear receptor corepressor−histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185–7191.
Shimada H, Ichikawa H, Nakamura S, Katsu R, Iwasa M, Kitabayashi I et al. Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. Blood 2000; 96: 655–663.
Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890–2904.
Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8: 743–750.
Yang G, Khalaf W, van de Locht L, Jansen JH, Gao M, Thompson MA et al. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol 2005; 25: 5869–5879.
Uchida H, Zhang J, Nimer SD . AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 1997; 158: 2251–2258.
Yang G, Thompson MA, Brandt SJ, Hiebert SW . Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 2007; 26: 91–101.
Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916–4921.
Alvarez-Martinez MT, Porte F, Liautard JP, Sri Widada J . Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes. Biochim Biophys Acta 1997; 1339: 331–340.
Canaider S, Solito E, DeCoupade C, Flower RJ, Russo-Marie F, Goulding NJ et al. Increased apoptosis in U937 cells over-expressing lipocortin 1 (annexin I). Life Sci 2000; 66: L265–L270.
Kwon SH, Ahn SH, Kim YK, Bae G-U, Yoon JW, Hong S et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002; 277: 2073–2080.
Reville K, Crean JK, Vivers S, Dransfield I, Godson C . Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J Immunol 2006; 176: 1878–1888.
Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959–967.
Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N . Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031–2036.
Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, Murayama T et al. Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br J Haematol 1995; 89: 805–811.
Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R . NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080–1086.
Li C, Wong WH . Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31–36.